Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers
Pharmacy Times
JULY 16, 2025
The updated definition for HRMM is increasingly important as there is an increased focus on how to improve outcomes for patients with HRMM, functional HRMM, and true extramedullary disease. The findings of the DeLLphi-304 study demonstrated improved OS of tarlatamab compared with single-agent chemotherapy (median OS [mOS], 13.6
Let's personalize your content